Critical Comparison: DBV Technologies (NASDAQ:DBVT) versus PharmaCyte Biotech (NASDAQ:PMCB)

PharmaCyte Biotech (NASDAQ:PMCB) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Valuation and Earnings

This table compares PharmaCyte Biotech and DBV Technologies”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PharmaCyte Biotech	N/A	N/A	$330,000.00	($1.20)	-1.50
DBV Technologies	$15.73 million	5.32	-$72.73 million	($0.84)	-1.03

PharmaCyte Biotech has higher earnings, but lower revenue than DBV Technologies. PharmaCyte Biotech is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares PharmaCyte Biotech and DBV Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PharmaCyte Biotech	N/A	1.38%	0.71%
DBV Technologies	-638.21%	-74.41%	-55.84%

Insider and Institutional Ownership

34.2% of PharmaCyte Biotech shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 1.0% of PharmaCyte Biotech shares are held by company insiders. Comparatively, 1.9% of DBV Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

PharmaCyte Biotech has a beta of -0.21, indicating that its stock price is 121% less volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for PharmaCyte Biotech and DBV Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PharmaCyte Biotech	0	0	0	0	N/A
DBV Technologies	1	0	2	0	2.33

DBV Technologies has a consensus price target of $4.67, indicating a potential upside of 438.57%. Given DBV Technologies’ higher probable upside, analysts plainly believe DBV Technologies is more favorable than PharmaCyte Biotech.

Summary

DBV Technologies beats PharmaCyte Biotech on 8 of the 12 factors compared between the two stocks.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.